mAbs and vaccines against SARS CoV-2

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications & trials

Abstract

A vaccine against SARS CoV 2 virus would be highly significant in preventing outbreaks which are known to occur naturally. SARS CoV 2 is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic for which there is no effective treatment or cure. Therefore, vaccine studies are critically important for protection against infection. We developed a highly effective vaccine strategy and antibody identification strategy for Ebola virus infection in non-human primates. Our laboratory has demonstrated that protective immunity to Ebola can be generated with a single inoculation of an adenoviral vector vaccine, a result with significant implications for conducting enhanced ring vaccination during an Ebola outbreak. We aim to use a similar strategy for SARS CoV2.